IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Application of:)
JENKINS, Peter James et al.) Group Art Unit: 1623
Application No.: 10/776,188)) Examiner: E. Peselev
Filed: February 12, 2004))
For: PREPARATION AND DIABETIC USE OF GIBBERELLINS	,) Confirmation No.: 3089)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(d)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(d), Applicants bring to the attention of the Examiner the documents on the attached listing. This Supplemental Information Disclosure Statement is being filed after an Office Action and is accompanied by a fee of \$180.00 as specified under § 1.17(p) and a certification as specified under § 1.97(e)(2). Applicants respectfully request that the Examiner consider the listed document and indicate that it was considered by making appropriate notation on the attached form.

Based on reasonable inquiry, no document listed in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and no document listed in this Supplemental Information Disclosure Statement was known to any individual designated in 37 C.F.R.

§ 1.56(c) more than three months prior to the filing date of this Supplemental Information Disclosure Statement.

A copy of the listed non-patent literature documents are enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notation on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed document is material or constitute "prior art." If the Examiner applies this document as prior art against any claim in the application and Applicants determine that the cited document does not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such a document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed document, should the document be applied against the claims of the present application.

If there are any additional fees due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Ву

Respectfully submitted,

Mike McGurk Reg. No. 32,045

FINNEGAN, HENDERSON, FARABOW,

GARRETT & DUNNER, L.L.P.

Dated: November 16, 2007